Latest Tax Refunds News

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Tabcorp Holdings reported a modest 1% revenue increase for the half year ending December 2025, while adjusted net profit after tax jumped 61.5%, prompting a 50% rise in the interim dividend.

Elixir Energy has locked in a $10 million debt facility secured against its FY26 R&D tax refund to fund the Lorelle-3 appraisal well activities in Queensland’s Taroom Trough. This financial move aims to bolster working capital during a busy operational period.

Legend Mining has received an $811,458 cash refund from the Australian Taxation Office for its FY2025 R&D claim, lifting its cash position to nearly $11 million.

McPherson’s Limited has confirmed a $3.3 million total tax benefit following amended assessments by the ATO, linked to deductible costs from a strategic alliance announced in 2022.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Commonwealth Bank of Australia reported a 5% rise in net profit for the half-year ended December 2025, balancing lending growth with margin pressures and increased technology investment.

Delorean Corporation has completed the $53 million Yarra Valley Water bioenergy facility and progressed key projects in South Australia and Victoria, supported by strong government grants and renewable gas policies.

Australian Rare Earths Limited (ASX – AR3) has made significant strides in advancing its Koppamurra Rare Earths Project, securing pilot-scale processing at ANSTO’s new facility and raising $6 million post-quarter to fund development. Concurrently, promising uranium targets have been identified at its Overland Project.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Mithril Silver and Gold Limited reports strong exploration progress at its Copalquin project in Mexico, with resource expansion drilling underway and a new acquisition adding to its portfolio. The company ends the quarter with a robust cash position, setting the stage for an active 2026.

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.